Qinxia Xu

12 Middle Urumqi Road
Shanghai, 200040, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

PPP3R1 Promoter Polymorphism (Allelic Variation) Affects Tacrolimus Treatment Efficacy by Modulating E2F6 Binding Affinity.

PPP3R1 Promoter Polymorphism (Allelic Variation) Affects Tacrolimus Treatment Efficacy by Modulating E2F6 Binding Affinity.

Journal: Biomedicines

Published: October 28, 2024

Prophylactic trimethoprim-sulfamethoxazole is safe in adult patients with primary central nervous system lymphoma receiving high-dose methotrexate.

Prophylactic trimethoprim-sulfamethoxazole is safe in adult patients with primary central nervous system lymphoma receiving high-dose methotrexate.

Journal: Annals of hematology

Published: September 29, 2024

TLR10 genotypes affect long-term graft function in tacrolimus-treated solid organ transplant recipients.

TLR10 genotypes affect long-term graft function in tacrolimus-treated solid organ transplant recipients.

Journal: International immunopharmacology

Published: February 17, 2022

CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.

CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.

Journal: Gene

Published: May 31, 2021

Correction to: CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic syndrome.

Correction to: CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic syndrome.

Journal: European journal of clinical pharmacology

Published: January 30, 2021

FKBP-CaN-NFAT pathway polymorphisms selected by in silico biological function prediction are associated with tacrolimus efficacy in renal transplant patients.

FKBP-CaN-NFAT pathway polymorphisms selected by in silico biological function prediction are associated with tacrolimus efficacy in renal transplant patients.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: September 02, 2020

CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria.

CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria.

Journal: European journal of clinical pharmacology

Published: April 04, 2019

FKBP1A rs6041749 polymorphism is associated with allograft function in renal transplant patients.

FKBP1A rs6041749 polymorphism is associated with allograft function in renal transplant patients.

Journal: European journal of clinical pharmacology

Published: May 31, 2018

NFATC1 genotypes affect acute rejection and long-term graft function in cyclosporine-treated renal transplant recipients.

NFATC1 genotypes affect acute rejection and long-term graft function in cyclosporine-treated renal transplant recipients.

Journal: Pharmacogenomics

Published: March 01, 2017

FOXP3 rs3761548 polymorphism is associated with tacrolimus-induced acute nephrotoxicity in renal transplant patients.

FOXP3 rs3761548 polymorphism is associated with tacrolimus-induced acute nephrotoxicity in renal transplant patients.

Journal: European journal of clinical pharmacology

Published: June 27, 2016

Showing 1-10 of 10

Last Updated: 09/26/2026